Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Clinical trial NCT03974217 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03974217
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-08-01
- Primary completion
- 2025-04-03
- Enrollment
- 13
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.